Sign up
Pharma Capital

Calithera Biosciences shares dip on $50 million secondary offering

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close
Share document
Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases

Calithera Biosciences Inc (NASDAQ:CALA) shares hit a stumbling block after the company announced the pricing of a $50 million secondary offering late Tuesday.

The clinical stage biotechnology company will offer 12.5 million shares at $4 per share, 15% lower than its Tuesday close.

Investors responded to the dilutive measure in kind, dropping the share price almost 13% to $4.13.

READ: Pressure BioSciences ultra high-pressure HUB platform shines in food safety studies

The offering is expected to close on June 21. In its Tuesday statement, the company did not specify what it would do with the proceeds.

Calithera Biosciences is a South San Francisco-based company focused on developing small-molecule treatments for cancer and other diseases.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

1551807154_andrew.jpg


Register here to be notified of future CALA Company articles
View full CALA profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.